Friday, May 10 2024
03:00 PM – 03:15 PM ET - Room 307-308
274: Systemic AAV Gene Therapy with CNS-Targeted Engineered Capsids Achieves Significant GCase Activity Increases in the Primate Brain to Support the Potential Treatment of GBA-PD
Nicholas Flytzanis - PhD
Capsida Biotherapeutics, Inc.
Disclosures: N.C. Flytzanis: 1; Commercial Interest i.e. Company X; Capsida Biotherapeutics, Inc.. 1; What was received? i.e. Honorarium; Salary, Stock. 1; For what role? i.e. Speaker; Employment.
Related Abstract